ペプチド治療薬の市場規模、シェア、動向分析レポート：用途別、タイプ別、メーカー別、投与経路別、合成技術別、地域別、セグメント予測、2024年～2030年

ペプチド治療薬市場の成長と動向：

Grand View Research, Inc.の新しいレポートによると、世界のペプチド治療薬市場規模は2030年までに664億1,000万米ドルに達する見込みです。

2024年から2030年までのCAGRは6.1%で成長する見込みです。がんやその他の生活習慣病の治療には、副作用の少ない効率的で即効性のある治療薬への需要が高まっており、市場の成長を促進すると予想されています。がんの罹患率が上昇していることから、他の治療法や低コストの治療法の模索と導入が求められており、市場の牽引役となることが予想されます。さらに、老人人口の増加は、がんや糖尿病などの対象疾患の罹患率を誘発することにより、消費者基盤を拡大すると予想され、ペプチド治療薬の需要を促進すると期待されています。

国際がん研究機関（GLOBOCAN 2020）の報告書によると、2020年に新たに診断されるがん患者は世界で1,929万2,789人となり、がんによる死亡者数は995万8,133人となります。さらに、がんの5年間の有病率は世界で5,055万287人になると予測されました。2040年には、世界の新規がん患者数は2,888万7,940人に達すると予測されています。その結果、世界中でがんの発生率が高くなることは、予測期間中、ペプチド治療薬の開発に重要な役割を果たすことになります。それに加えて、化学療法や放射線療法の悪影響に対する医療提供者や患者の意識の高まりが、ペプチドベースの薬剤のような代替治療への重点の高まりに影響を与える主な要因となっています。

ペプチド製造プロセスにおける技術的進歩が、予測期間中の市場を牽引しています。メーカーやサプライヤーは、少ない時間と資本投資で効率的な薬剤分子を製造するための新技術の採用に注力しています。精製や自動化プロセスの改善、廃棄物の発生が少ないことも、市場成長のさらなる要因となっています。例えば、アムジェン社は2022年3月、ノースカロライナ州ホリースプリングスに最新のバイオ製造施設を正式に開設すると発表しました。2025年に開設予定のこの施設は、がんや心臓病といった深刻な病気を治療するアムジェンの医薬品の成長に対応するのに役立つと思われます。

COVID-19の大流行は、診断の遅れ、治療介入、がん治療のための費用対効果の高い治療薬の開発に焦点を当てた臨床試験の阻害など、がん治療のスペクトラムに拍車をかけると予想されており、がん治療のためのペプチド治療薬も例外ではない、とNature Cancer, 2020に掲載された研究論文は述べています。急性呼吸窮迫症候群（ARDS）や重症急性呼吸器感染症によって引き起こされる他の呼吸器疾患の治療のための15の合成ペプチドなど、2020年5月現在、COVID-19の治療のための21のペプチド医薬品があります。しかし、現在、がんや代謝性疾患などにおけるペプチド治療薬の実用化は、薬剤不足や運用上の問題、COVID-19以外の治療薬を含む臨床試験の進捗の遅れによって妨げられています。

例えば、2022年5月、EVER Pharma社は、ボルテゾミブが症候性骨髄腫およびマントル細胞リンパ腫の治療薬としてEU全域で承認を取得したと発表した1。2022年5月、欧州委員会は、急性および慢性移植片対宿主病に対するノバルティスのJakaviポストステロイド療法を承認しました。Jakaviは、欧州でステロイド抵抗性の移植片対宿主病患者に対して広く使用できる最初のJAK1/2阻害剤となります。2021年9月、Nimble Therapeutics社とIncyte社は、さらなる新規ペプチド治療薬を発見するための戦略的共同研究を開始しました。

ペプチド治療薬市場レポートハイライト

• 用途別では、従来の治療法よりも代替治療法の需要が高まっていることから、2023年にはがんが第2位の売上シェアを占めました。ペプチドは、がん治療における潜在的な治療薬として使用されています。
• ジェネリック医薬品分野は、ブロックバスターペプチドの特許切れや、ジェネリック医薬品のイントロダクション関連する政府の積極的な取り組みにより、売上高が増加すると予想されます。
• アウトソーシング製造分野は、複雑な手順が要求されることや、製造コストの削減に役立つアウトソーシングへの嗜好の変化により、予測期間中に最も速いCAGRで成長すると予想されます。
• 合成技術別では、ハイブリッド技術が予測期間中に最も急成長する見込みです。固相と液相のペプチド合成における時間の節約や使いやすさなど、この技術に関連する利点が成長を後押しする主な要因です。
• 北米は、ゲノミクスとプロテオミクス製品に関する認知度の高さ、確立された研究開発インフラ、資金調達イニシアチブの高まりにより、2023年の売上高で最大のシェアを占めました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ペプチド治療薬市場の変数、動向、および範囲

• ペプチド治療薬市場の系統展望
  • 親市場の見通し
  • アンシラリーマーケット
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ペプチド治療薬市場分析ツール
  • ポーターのファイブフォース分析
  • PESTLE分析

第4章 ペプチド治療薬市場 - 用途別セグメント分析、2018年～2030年

• ペプチド治療薬市場：用途変動分析
• 用途別
  • がん
  • 代謝障害
  • 心血管疾患
  • 呼吸器疾患
  • 胃腸疾患
  • 感染症
  • 痛み
  • 皮膚疾患
  • 神経学的障害
  • 腎疾患
  • その他

第5章 ペプチド治療薬市場：タイプ別セグメント分析、2018年～2030年

• ペプチド治療薬市場：タイプの変動分析
• タイプ別
  • ジェネリック
  • 革新的

第6章 ペプチド治療薬市場：メーカータイプ別セグメント分析、2018年～2030年

• ペプチド治療薬市場：メーカータイプの変動分析
• メーカーの種類別
  • 社内
  • 外部委託

第7章 ペプチド治療薬市場：投与経路別セグメント分析、2018年～2030年

• ペプチド治療薬市場：投与変動分析
• 投与経路別
  • 非経口経路
  • 経口
  • 肺
  • 粘膜
  • その他

第8章 ペプチド治療薬市場- 合成技術別セグメント分析、2018年～2030年

• ペプチド治療薬市場：合成技術変動分析
• 合成技術別
  • 固相ペプチド合成（SPPS）
  • 液相ペプチド合成（LPPS）
  • ハイブリッド技術

第9章 ペプチド治療薬市場：用途、種類、メーカーの種類、投与経路、合成技術別の地域推定・動向分析

• ペプチド治療薬市場：地域別の見通し
• 北米
  • 北米ペプチド治療薬市場推計・予測、2018年～2030年
  • 米国
  • カナダ
• 欧州
  • 欧州のペプチド治療薬市場推計・予測、2018年～2030年
  • 英国
  • ドイツ
  • フランス
  • スペイン
  • イタリア
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • アジア太平洋のペプチド治療薬市場推計・予測、2018年～2030年
  • 日本
  • 中国
  • インド
  • オーストラリア
  • タイ
  • 韓国
  • その他アジア太平洋のペプチド治療薬市場推計・予測、2018年～2030年
• ラテンアメリカ
  • ラテンアメリカのペプチド治療薬市場推計・予測、2018年～2030年
  • ブラジル
  • メキシコ
  • アルゼンチン
  • その他ラテンアメリカのペプチド治療薬市場推計・予測、2018年～2030年
• 中東・アフリカ
  • 中東・アフリカのペプチド治療薬市場推計・予測、2018年～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第10章 競合情勢

• 企業の分類
• 戦略マッピング
  • 新製品の発売
  • パートナーシップ
  • 取得
  • コラボレーション
  • 資金調達
• 主要企業の市場シェア分析、2023年
• 企業プロファイル
  • Eli Lilly and Company
  • Pfizer Inc.
  • Amgen Inc.
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • AstraZeneca
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Novo Nordisk A/S
  • GlaxoSmithKline plc.
  • Ironwood Pharmaceuticals, Inc.
  • Radius Health, Inc.
  • Ipsen Pharma

第11章 結論

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviation
• Table 3 North America peptide therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Billion)
• Table 4 North America peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 5 North America peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 6 North America peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 7 North America peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 8 North America peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 9 U.S. peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 10 U.S. peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 11 U.S. peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 12 U.S. peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 13 U.S. peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 14 Canada peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 15 Canada peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 16 Canada peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 17 Canada peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 18 Canada peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 19 Europe peptide therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Billion)
• Table 20 Europe peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 21 Europe peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 22 Europe peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 23 Europe peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 24 Europe peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 25 UK peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 26 UK peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 27 UK peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 28 UK peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 29 UK peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 30 Germany peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 31 Germany peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 32 Germany peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 33 Germany peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 34 Germany peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 35 France peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 36 France peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 37 France peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 38 France peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 39 France peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 40 Spain peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 41 Spain peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 42 Spain peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 43 Spain peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 44 Spain peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 45 Italy peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 46 Italy peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 47 Italy peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 48 Italy peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 49 Italy peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 50 Denmark peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 51 Denmark peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 52 Denmark peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 53 Denmark peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 54 Denmark peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 55 Sweden peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 56 Sweden peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 57 Sweden peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 58 Sweden peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 59 Sweden peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 60 Norway peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 61 Norway peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 62 Norway peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 63 Norway peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 64 Norway peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 65 Asia Pacific peptide therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Billion)
• Table 66 Asia Pacific peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 67 Asia Pacific peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 68 Asia Pacific peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 69 Asia Pacific peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 70 Asia Pacific peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 71 Japan peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 72 Japan peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 73 Japan peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 74 Japan peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 75 Japan peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 76 China peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 77 China peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 78 China peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 79 China peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 80 China peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 81 India peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 82 India peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 83 India peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 84 India peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 85 India peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 86 South Korea peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 87 South Korea peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 88 South Korea peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 89 South Korea peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 90 South Korea peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 91 Australia peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 92 Australia peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 93 Australia peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 94 Australia peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 95 Australia peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 96 Thailand peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 97 Thailand peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 98 Thailand peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 99 Thailand peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 100 Thailand peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 101 Latin America peptide therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Billion)
• Table 102 Latin America peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 103 Latin America peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 104 Latin America peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 105 Latin America peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 106 Latin America peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 107 Brazil peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 108 Brazil peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 109 Brazil peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 110 Brazil peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 111 Brazil peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 112 Mexico peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 113 Mexico peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 114 Mexico peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 115 Mexico peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 116 Mexico peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 117 Argentina peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 118 Argentina peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 119 Argentina peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 120 Argentina peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 121 Argentina peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 122 MEA peptide therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Billion)
• Table 123 MEA peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 124 MEA peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 125 MEA peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 126 MEA peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 127 MEA peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 128 South Africa peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 129 South Africa peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 130 South Africa peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 131 South Africa peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 132 South Africa peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 133 UAE peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 134 UAE peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 135 UAE peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 136 UAE peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 137 UAE peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 138 Saudi Arabia peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 139 Saudi Arabia peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 140 Saudi Arabia peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 141 Saudi Arabia peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 142 Saudi Arabia peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
• Table 143 Kuwait peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
• Table 144 Kuwait peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
• Table 145 Kuwait peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
• Table 146 Kuwait peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
• Table 147 Kuwait peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)

List of Figures

• Fig. 1 Peptide therapeutics market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Value chain-based sizing & forecasting
• Fig. 6 QFD modelling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Application segment snapshot
• Fig. 10 Type and type of manufacturers segment snapshot
• Fig. 11 Route of administration and synthesis technology segment snapshot
• Fig. 12 Competitive landscape snapshot
• Fig. 13 Pharmaceutical market, (USD Billion)
• Fig. 14 Market dynamics
• Fig. 15 The most common cancers globally are listed in the table below
• Fig. 16 Global number of new cases caused by top 11 cancer types in 2023 (in thousands)
• Fig. 17 The figure below shows the phase of therapeutic peptides in clinical trials:
• Fig. 18 Porter's five forces analysis
• Fig. 19 PESTLE analysis
• Fig. 20 Peptide therapeutics market: Application outlook and key takeaways
• Fig. 21 Peptide therapeutics market: Application movement analysis
• Fig. 22 Cancer market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Metabolic disorders market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Cardiovascular disorders market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Respiratory disorders market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Gastrointestinal disorders market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Pain market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 Dermatological disorders market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Neurological disorders market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Renal disorders market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Peptide therapeutics market: Type outlook and key takeaways
• Fig. 34 Peptide therapeutics market: Type movement analysis
• Fig. 35 Generic market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 36 Innovative market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Peptide therapeutics market: Type of manufacturers outlook and key takeaways
• Fig. 38 Peptide therapeutics market: Type of manufacturers movement analysis
• Fig. 39 In-house market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 40 Outsourced market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 41 Peptide therapeutics market: Route of administration outlook and key takeaways
• Fig. 42 Peptide therapeutics market: Route of administration movement analysis
• Fig. 43 Parenteral route market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 44 Oral route market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 45 Pulmonary market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 46 Mucosal market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 47 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 48 Peptide therapeutics market: Synthesis technology outlook and key takeaways
• Fig. 49 Peptide therapeutics market: Synthesis technology movement analysis
• Fig. 50 Solid Phase Peptide Synthesis (SPPS) market estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 51 Liquid Phase Peptide Synthesis (LPPS) Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 52 Hybrid technology market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 53 Peptide therapeutics market revenue, by region, 2022 & 2030 (USD Million)
• Fig. 54 Regional marketplace: Key takeaways
• Fig. 55 Regional marketplace: Key takeaways
• Fig. 56 North America peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Key country dynamics
• Fig. 58 Target disease prevalence
• Fig. 59 U.S. peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Key country dynamics
• Fig. 61 Target disease prevalence
• Fig. 62 Canada peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Europe peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Key country dynamics
• Fig. 65 Target disease prevalence
• Fig. 66 UK peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Key country dynamics
• Fig. 68 Target disease prevalence
• Fig. 69 Germany peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 Key country dynamics
• Fig. 71 Target disease prevalence
• Fig. 72 France peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Key country dynamics
• Fig. 74 Target disease prevalence
• Fig. 75 Spain peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 76 Key country dynamics
• Fig. 77 Target disease prevalence
• Fig. 78 Italy peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Key country dynamics
• Fig. 80 Target disease prevalence
• Fig. 81 Denmark peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 82 Key country dynamics
• Fig. 83 Target disease prevalence
• Fig. 84 Sweden peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 85 Key country dynamics
• Fig. 86 Target disease prevalence
• Fig. 87 Norway peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 88 Rest of Europe peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 89 Asia Pacific peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 Key country dynamics
• Fig. 91 Target disease prevalence
• Fig. 92 Japan peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 93 Key country dynamics
• Fig. 94 Target disease prevalence
• Fig. 95 China peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 96 Key country dynamics
• Fig. 97 Target disease prevalence
• Fig. 98 India peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 99 Key country dynamics
• Fig. 100 Target disease prevalence
• Fig. 101 Australia peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 102 Key country dynamics
• Fig. 103 Thailand peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 104 Key country dynamics
• Fig. 105 South Korea peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 106 Rest of Asia Pacific peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 107 Latin America peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 108 Key country dynamics
• Fig. 109 Target disease prevalence
• Fig. 110 Brazil peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 111 Key country dynamics
• Fig. 112 Target disease prevalence
• Fig. 113 Mexico peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 114 Key country dynamics
• Fig. 115 Target disease prevalence
• Fig. 116 Argentina peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 117 Rest of Latin America peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 118 MEA peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 119 Key country dynamics
• Fig. 120 Target disease prevalence
• Fig. 121 South Africa peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 122 Key country dynamics
• Fig. 123 Target disease prevalence
• Fig. 124 Saudi Arabia peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 125 Key country dynamics
• Fig. 126 Target disease prevalence
• Fig. 127 UAE peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 128 Key country dynamics
• Fig. 129 Target disease prevalence
• Fig. 130 Kuwait peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 131 Rest of MEA peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)

Peptide Therapeutics Market Growth & Trends:

The global peptide therapeutics market size is expected to reach USD 66.41 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to grow at a CAGR of 6.1% from 2024 to 2030. Increasing demand for efficient and rapid-acting therapeutics for the treatment of cancer and other lifestyle-associated disorders, which result in lesser adverse effects, is anticipated to propel market growth. The rising incidence of cancer calls for exploring and introducing other means of therapies and low-cost treatment alternatives is expected to drive the market. Moreover, the growing geriatric population is expected to widen the consumer base by triggering the incidence rate of target diseases such as cancer and diabetes, which is expected to drive the demand for peptide therapeutics.

As per the International Agency for Research on Cancer (GLOBOCAN 2020) report, there will be 19,292,789 new cancer cases diagnosed globally in 2020, with 9,958,133 cancer deaths. Furthermore, the five-year prevalence of cancer was projected to be 50,550,287 worldwide. The global number of new cases of cancer is projected to reach 28,887,940 by 2040. As a result, the higher incidence of cancers around the world is set to perform an important role in the development of peptide therapeutics over the forecast period. Besides that, increasing awareness among health care providers and patients about the negative effects of chemotherapy and/or radiation therapy is a primary factor influencing the increased emphasis on alternative therapeutics like peptide-based drugs.

Technological advancements in the peptide manufacturing process are driving the market during the forecast period. Manufacturers and suppliers are focusing on the adoption of novel technologies to manufacture efficient drug molecules with low time and capital investment. Improvement in purification and automation process and less generation of waste are additional factors contributing to the market growth. For instance, in March 2022, Amgen announced the official opening of its latest bio-manufacturing facility in Holly Springs, North Carolina. The facility, which is set to open in 2025, will help cope with the growth of Amgen's medicines, which treat serious diseases like cancer and heart disease.

The COVID-19 pandemic is anticipated to spur the spectrum of cancer care, which includes delayed diagnoses, therapeutic interventions, and the impeding of clinical trials focused on developing cost-effective therapeutics for cancer treatment, with peptide therapeutics for cancer treatment being no exception, as per a research article published in Nature Cancer, 2020. There have been 21 peptide drugs in therapies for the treatment of COVID-19 as of May 2020, such as 15 synthetic peptides for the therapies of acute respiratory distress syndrome (ARDS) as well as other respiratory illnesses induced by severe acute respiratory infection. However, current implementations of peptide therapeutics in oncological and metabolic disorders and other fields have been hampered by drug shortages, operational problems, and the slow progress of clinical trials involving non-COVID-19 therapeutics.

For instance, in May 2022, EVER Pharma announced that Bortezomib has received EU-wide approval for the treatment of individuals with symptomatic myeloma and mantle cell lymphoma1. In May 2022, The European Commission approved Novartis' Jakavi post-steroid therapy for acute and chronic graft-versus-host ailments. Jakavi will be the first JAK1/2 inhibitor widely available for patients in Europe with steroid-refractory graft-versus-host ailment. In September 2021, Nimble Therapeutics and Incyte entered into strategic collaborative research to discover additional new peptide therapies.

Peptide Therapeutics Market Report Highlights:

• By application, cancer held the second-largest revenue share in 2023 owing to the increasing demand for alternative therapeutics over conventional treatment options. Peptides are being used as potential therapeutic agents in cancer treatment
• The generic type segment is expected to showcase an upward shift due to the patent expiration of blockbuster peptides and supportive government initiatives pertaining to the introduction of the generic class
• Outsourcing manufacturing segment is anticipated to grow at the fastest CAGR during the forecast period owing to the requirements of complex procedures and a shift in preference toward outsourcing, which helps in eliminating the cost of production
• By synthesis technology, hybrid technology is expected to witness the fastest growth over the forecast period. Benefits associated with this technology such as time conservation and ease of usage for both solid- and liquid-phase peptide synthesis are the key factors affirming growth
• North America held the largest share in terms of revenue in 2023 owing to a higher level of awareness pertaining to genomics and proteomics products, well-established R&D infrastructure, and rising funding initiatives

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation
  • 1.1.1 Regional Scope
  • 1.1.2 Market Definitions
  • 1.1.3 Estimates and Forecast Timeline
• 1.2 Objectives
  • 1.2.1 Objective - 1
  • 1.2.2 Objective - 2
  • 1.2.3 Objective - 3
• 1.3 Research Methodology
• 1.4 Information Procurement
  • 1.4.1 Purchased Database
  • 1.4.2 GVR's Internal Database
  • 1.4.3 Secondary Sources
  • 1.4.4 Primary Research
  • 1.4.5 Details of Primary Research
• 1.5 Information or Data Analysis
  • 1.5.1 Data Analysis Models
• 1.6 Market Formulation & Validation
• 1.7 Model Details
  • 1.7.1 Commodity Flow Analysis
    • 1.7.1.1 Approach 1: Commodity Flow Approach
    • 1.7.1.2 Approach 2: Country-wise market estimation using bottom-up approach
• 1.8 List of Secondary Sources
• 1.9 List of Abbreviations

Chapter 2 Executive Summary

• 2.1 Market Snapshot
• 2.2 Application Segment Snapshot
• 2.3 Type and Type of Manufacturers Segment Snapshot
• 2.4 Route of Administration and Synthesis Technology Segment Snapshot
• 2.5 Competitive Landscape Snapshot

Chapter 3 Peptide Therapeutics Market Variables, Trends, and Scope

• 3.1 Peptide Therapeutics Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
  • 3.1.2 Ancillary Market
• 3.2 Market Dynamics
  • 3.2.1 Market Driver Analysis
    • 3.2.1.1 Increasing Incidence of Cancer
    • 3.2.1.1.1 Cancer Incidence Data
    • 3.2.1.2 Rising Prevalence of Metabolic Disorders
    • 3.2.1.3 Presence of Strong Product Pipeline
    • 3.2.1.4 Technological Advancements
  • 3.2.2 Market Restraint Analysis
    • 3.2.2.1 Increasing Complexity of Peptides
    • 3.2.2.2 High Cost of Manufacturing Equipment
• 3.3 Peptide Therapeutics Market Analysis Tools
  • 3.3.1 Porter's Five Forces Analysis
  • 3.3.2 PESTLE Analysis

Chapter 4 Peptide Therapeutics Market - Segment Analysis, by Application, 2018 - 2030 (USD Million)

• 4.1 Peptide Therapeutics Market: Application Movement Analysis
• 4.2 Peptide Therapeutics Market Estimates & Forecast, By Application (USD Million)
  • 4.2.1 Cancer
  • 4.2.2 Metabolic Disorders
  • 4.2.3 Cardiovascular Disorders
  • 4.2.4 Respiratory Disorders
  • 4.2.5 Gastrointestinal Disorders
  • 4.2.6 Infectious Diseases
  • 4.2.7 Pain
  • 4.2.8 Dermatological Disorders
  • 4.2.9 Neurological Disorders
  • 4.2.10 Renal Disorders
  • 4.2.11 Others

Chapter 5 Peptide Therapeutics Market: Segment Analysis, by Type, 2018 - 2030 (USD Million)

• 5.1 Peptide Therapeutics Market: Type Movement Analysis
• 5.2 Peptide Therapeutics Market Estimates & Forecast, by Type (USD Million)
  • 5.2.1 Generic
  • 5.2.2 Innovative

Chapter 6 Peptide Therapeutics Market: Segment Analysis, By Type Of Manufacturers, 2018 - 2030 (USD Million)

• 6.1 Peptide Therapeutics Market: Type of Manufacturers Movement Analysis
• 6.2 Peptide Therapeutics Market Estimates & Forecast, by Type Of Manufacturers (USD Million)
  • 6.2.1 In-house
  • 6.2.2 Outsourced

Chapter 7 Peptide Therapeutics Market: Segment Analysis, by Route Of Administration, 2018 - 2030 (USD Million)

• 7.1 Peptide Therapeutics Market: Route Of Administration Movement Analysis
• 7.2 Peptide Therapeutics Market Estimates & Forecast, by Route Of Administration (USD Million)
  • 7.2.1 Parenteral Route
  • 7.2.2 Oral Route
  • 7.2.3 Pulmonary
  • 7.2.4 Mucosal
  • 7.2.5 Others

Chapter 8 Peptide Therapeutics Market - Segment Analysis, by Synthesis Technology, 2018 - 2030 (USD Million)

• 8.1 Peptide Therapeutics Market: Synthesis Technology Movement Analysis
• 8.2 Peptide Therapeutics Market Estimates & Forecast, By Synthesis Technology (USD Million)
  • 8.2.1 Solid Phase Peptide Synthesis (SPPS)
  • 8.2.2 Liquid Phase Peptide Synthesis (LPPS)
  • 8.2.3 Hybrid Technology

Chapter 9 Peptide Therapeutics Market: Regional Estimates and Trend Analysis by Application, Type, Type of Manufacturer, Route of Administration, and Synthesis Technology

• 9.1 Peptide Therapeutics Market: Regional Outlook
• 9.2 North America
  • 9.2.1 North America Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.2.2 U.S.
    • 9.2.2.1 Key Country Dynamics
    • 9.2.2.2 Target Disease Prevalence
    • 9.2.2.3 U.S. Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.2.4 Competitive/Market Scenario
    • 9.2.2.5 Regulatory Framework
    • 9.2.2.6 Reimbursement Scenario
  • 9.2.3 Canada
    • 9.2.3.1 Key Country Dynamics
    • 9.2.3.2 Target Disease Prevalence
    • 9.2.3.3 Canada Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.3.4 Competitive/Market Scenario
    • 9.2.3.5 Regulatory Framework
    • 9.2.3.6 Reimbursement Scenario
• 9.3 Europe
  • 9.3.1 Europe Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.2 UK
    • 9.3.2.1 Key Country Dynamics
    • 9.3.2.2 Target Disease Prevalence
    • 9.3.2.3 UK Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.2.4 Competitive/Market Scenario
    • 9.3.2.5 Regulatory Framework
    • 9.3.2.6 Reimbursement Scenario
  • 9.3.3 Germany
    • 9.3.3.1 Key Country Dynamics
    • 9.3.3.2 Target Disease Prevalence
    • 9.3.3.3 Germany Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.3.4 Competitive/Market Scenario
    • 9.3.3.5 Regulatory Framework
    • 9.3.3.6 Reimbursement Scenario
  • 9.3.4 France
    • 9.3.4.1 Key Country Dynamics
    • 9.3.4.2 Target Disease Prevalence
    • 9.3.4.3 France Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.4.4 Competitive/Market Scenario
    • 9.3.4.5 Regulatory Framework
    • 9.3.4.6 Reimbursement Scenario
  • 9.3.5 Spain
    • 9.3.5.1 Key Country Dynamics
    • 9.3.5.2 Target Disease Prevalence
    • 9.3.5.3 Spain Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.5.4 Competitive/Market Scenario
    • 9.3.5.5 Regulatory Framework
    • 9.3.5.6 Reimbursement Scenario
  • 9.3.6 Italy
    • 9.3.6.1 Key Country Dynamics
    • 9.3.6.2 Target Disease Prevalence
    • 9.3.6.3 Italy Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.6.4 Competitive/Market Scenario
    • 9.3.6.5 Regulatory Framework
    • 9.3.6.6 Reimbursement Scenario
  • 9.3.7 Denmark
    • 9.3.7.1 Key Country Dynamics
    • 9.3.7.2 Target Disease Prevalence
    • 9.3.7.3 Denmark Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.7.4 Competitive/Market Scenario
    • 9.3.7.5 Regulatory Framework
    • 9.3.7.6 Reimbursement Scenario
  • 9.3.8 Sweden
    • 9.3.8.1 Key Country Dynamics
    • 9.3.8.2 Target Disease Prevalence
    • 9.3.8.3 Sweden Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.8.4 Competitive/Market Scenario
    • 9.3.8.5 Regulatory Framework
    • 9.3.8.6 Reimbursement Scenario
  • 9.3.9 Norway
    • 9.3.9.1 Key Country Dynamics
    • 9.3.9.2 Target Disease Prevalence
    • 9.3.9.3 Norway Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.9.4 Competitive/Market Scenario
    • 9.3.9.5 Regulatory Framework
    • 9.3.9.6 Reimbursement Scenario
    • 9.3.9.7 Rest of Europe Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.4 Asia Pacific
  • 9.4.1 Asia Pacific Peptide Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.4.2 Japan
    • 9.4.2.1 Key Country Dynamics
    • 9.4.2.2 Target Disease Prevalence
    • 9.4.2.3 Japan Peptide Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.4.2.4 Competitive/Market Scenario
    • 9.4.2.5 Regulatory Framework
    • 9.4.2.6 Reimbursement Scenario
  • 9.4.3 China
    • 9.4.3.1 Key Country Dynamics
    • 9.4.3.2 Target Disease Prevalence
    • 9.4.3.3 China Peptide Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.4.3.4 Competitive/Market Scenario
    • 9.4.3.5 Regulatory Framework
    • 9.4.3.6 Reimbursement Scenario
  • 9.4.4 India
    • 9.4.4.1 Key Country Dynamics
    • 9.4.4.2 Target Disease Prevalence
    • 9.4.4.3 India Peptide Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.4.4.4 Competitive/Market Scenario
    • 9.4.4.5 Regulatory Framework
    • 9.4.4.6 Reimbursement Scenario
  • 9.4.5 Australia
    • 9.4.5.1 Key Country Dynamics
    • 9.4.5.2 Target Disease Prevalence
    • 9.4.5.3 Australia Peptide Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.4.5.4 Competitive/Market Scenario
    • 9.4.5.5 Regulatory Framework
  • 9.4.6 Thailand
    • 9.4.6.1 Key Country Dynamics
    • 9.4.6.2 Thailand Peptide Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.4.6.3 Competitive/Market Scenario
    • 9.4.6.4 Regulatory Framework
    • 9.4.6.5 Reimbursement Scenario
  • 9.4.7 South Korea
    • 9.4.7.1 Key Country Dynamics
    • 9.4.7.2 South Korea Peptide Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.4.7.3 Competitive/Market Scenario
    • 9.4.7.4 Regulatory Framework
    • 9.4.7.5 Reimbursement Scenario
  • 9.4.8 Rest of Asia Pacific Peptide Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 9.5 Latin America
  • 9.5.1 Latin America Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.2 Brazil
    • 9.5.2.1 Key Country Dynamics
    • 9.5.2.2 Target Disease Prevalence
    • 9.5.2.3 Brazil Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.2.4 Competitive/Market Scenario
    • 9.5.2.5 Regulatory Framework
    • 9.5.2.6 Reimbursement Scenario
  • 9.5.3 Mexico
    • 9.5.3.1 Key Country Dynamics
    • 9.5.3.2 Target Disease Prevalence
    • 9.5.3.3 Mexico Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.3.4 Competitive/Market Scenario
    • 9.5.3.5 Regulatory Framework
    • 9.5.3.6 Reimbursement Scenario
  • 9.5.4 Argentina
    • 9.5.4.1 Key Country Dynamics
    • 9.5.4.2 Target Disease Prevalence
    • 9.5.4.3 Argentina Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.4.4 Competitive/Market Scenario
    • 9.5.4.5 Regulatory Framework
    • 9.5.4.6 Reimbursement Scenario
  • 9.5.5 Rest of Latin America Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.6 MEA
  • 9.6.1 MEA Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.2 South Africa
    • 9.6.2.1 Key Country Dynamics
    • 9.6.2.2 Target Disease Prevalence
    • 9.6.2.3 South Africa Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.2.4 Competitive/Market Scenario
    • 9.6.2.5 Regulatory Framework
    • 9.6.2.6 Reimbursement Scenario
  • 9.6.3 Saudi Arabia
    • 9.6.3.1 Key Country Dynamics
    • 9.6.3.2 Target Disease Prevalence
    • 9.6.3.3 Saudi Arabia Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.3.4 Competitive/Market Scenario
    • 9.6.3.5 Regulatory Framework
    • 9.6.3.6 Reimbursement Scenario
  • 9.6.4 UAE
    • 9.6.4.1 Key Country Dynamics
    • 9.6.4.2 Target Disease Prevalence
    • 9.6.4.3 UAE Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.4.4 Competitive/Market Scenario
    • 9.6.4.5 Regulatory Framework
    • 9.6.4.6 Reimbursement Scenario
  • 9.6.5 Kuwait
    • 9.6.5.1 Key Country Dynamics
    • 9.6.5.2 Target Disease Prevalence
    • 9.6.5.3 Kuwait Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.5.4 Competitive/Market Scenario
    • 9.6.5.5 Regulatory Framework
    • 9.6.5.6 Reimbursement Scenario
    • 9.6.5.7 Rest of MEA Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10 Competitive Landscape

• 10.1 Company Categorization
• 10.2 Strategy Mapping
  • 10.2.1 New Product Launch
  • 10.2.2 Partnerships
  • 10.2.3 Acquisition
  • 10.2.4 Collaboration
  • 10.2.5 Funding
• 10.3 Key Company Market Share Analysis, 2023
• 10.4 Company Profiles
  • 10.4.1 Eli Lilly and Company
    • 10.4.1.1 Company overview
    • 10.4.1.2 Financial performance
    • 10.4.1.3 Product benchmarking
    • 10.4.1.4 Strategic initiatives
  • 10.4.2 Pfizer Inc.
    • 10.4.2.1 Company overview
    • 10.4.2.2 Financial performance
    • 10.4.2.3 Product benchmarking
    • 10.4.2.4 Strategic initiatives
  • 10.4.3 Amgen Inc.
    • 10.4.3.1 Company overview
    • 10.4.3.2 Financial performance
    • 10.4.3.3 Product benchmarking
    • 10.4.3.4 Strategic initiatives
  • 10.4.4 Takeda Pharmaceutical Company Limited
    • 10.4.4.1 Company overview
    • 10.4.4.2 Financial performance
    • 10.4.4.3 Product benchmarking
    • 10.4.4.4 Strategic initiatives
  • 10.4.5 Sanofi
    • 10.4.5.1 Company overview
    • 10.4.5.2 Financial performance
    • 10.4.5.3 Product benchmarking
    • 10.4.5.4 Strategic initiatives
  • 10.4.6 AstraZeneca
    • 10.4.6.1 Company overview
    • 10.4.6.2 Financial performance
    • 10.4.6.3 Product benchmarking
    • 10.4.6.4 Strategic initiatives
  • 10.4.7 Teva Pharmaceutical Industries Ltd.
    • 10.4.7.1 Company overview
    • 10.4.7.2 Financial performance
    • 10.4.7.3 Product benchmarking
    • 10.4.7.4 Strategic initiatives
  • 10.4.8 F. Hoffmann-La Roche Ltd
    • 10.4.10.1 Company overview
    • 10.4.10.2 Financial performance
    • 10.4.10.3 Product benchmarking
    • 10.4.10.4 Strategic initiatives
  • 10.4.9 Novartis AG
    • 10.4.9.1 Company overview
    • 10.4.9.2 Financial performance
    • 10.4.9.3 Product benchmarking
    • 10.4.9.4 Strategic initiatives
  • 10.4.10 Novo Nordisk A/S
    • 10.4.10.1 COMPANY OVERVIEW
    • 10.4.10.2 Product benchmarking
    • 10.4.10.3 Strategic initiatives
  • 10.4.11 GlaxoSmithKline plc.
    • 10.4.11.1 Company overview
    • 10.4.11.2 Product benchmarking
    • 10.4.11.3 Strategic initiatives
  • 10.4.12 Ironwood Pharmaceuticals, Inc.
    • 10.4.12.1 Company overview
    • 10.4.12.2 Product benchmarking
    • 10.4.12.3 Strategic initiatives
  • 10.4.13 Radius Health, Inc.
    • 10.4.13.1 Company overview
    • 10.4.13.2 Cepheid
    • 10.4.13.3 Financial performance
    • 10.4.13.4 Product benchmarking
    • 10.4.13.5 Strategic initiatives
  • 10.4.14 Ipsen Pharma
    • 10.4.14.1 Company overview
    • 10.4.14.2 Cepheid
    • 10.4.14.3 Financial performance
    • 10.4.14.4 Product benchmarking
    • 10.4.14.5 Strategic initiatives

Chapter 11 Conclusion